Enterprise Value
191.4M
Cash
71.22M
Avg Qtr Burn
N/A
Short % of Float
3.43%
Insider Ownership
17.39%
Institutional Own.
59.28%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NERLYNX Details Metastatic HER2-positive breast cancer | Approved Quarterly sales | |
NERLYNX Details HER2-positive breast cancer | Approved Quarterly sales | |
Alisertib Details Cancer, Small cell lung cancer | Phase 3 Update | |
Neratinib Details Metastatic Cervical Cancers | Phase 2 Data readout | |
Alisertib (2 combo trials) Details Breast cancer, ER+/HER2- breast cancer | Phase 2 Data readout | |
Neratinib Details Non-small cell lung carcinoma, Lung cancer | Phase 2 Update | |
Neratinib Details Bile duct cancer patients with HER2 mutations | Phase 2 Update | |
Neratinib (HKI-272) + fulvestrant + trastzuzumab Details Breast cancer, Metastatic breast cancer to brain, Metastatic breast cancer | Phase 2 Update | |
Trastuzumab Emtansine (T-DM1) With Neratinib Details Breast cancer | Phase 2 Update | |
Alisertib+pembrolizumab Details Cancer, Head and neck squamous cell carcinoma | Phase 1/2 Data readout |